This is the final post in our brief series on drug safety. If you missed any of the previous posts, here are the links: Why Monitoring Adverse Events And Drug Safety Signals Matters What Exactly Is An “Adverse Drug Reaction?” The Role Of Signal Detection In Drug Safety What Pharmacovigilance Means And Why It Matters […]
Posts Tagged ‘drug development’
Critical Components Of The Preclinical Stage Of FDA Drug Approval
Last time, I published a post that posed the question: why are prescription drugs in the U.S. so expensive? Today’s post is the first in a brief series that will attempt to provide an answer by looking each stage of the FDA drug approval process, starting with preclinical. Below are the key components of the […]
Pharma Leans On Private Equity To Fund Clinical Trials
In a time in which research and development costs are at an all-time high, The Wall Street Journal just shared how pharmaceutical companies are starting to look for outside help to fund trials: everything from phase II all the way through the commercial phase. Partnering with private equity firms, such as NovaQuest and Avillion, is […]
How Teva Is Leveraging IBM Watson To Improve Healthcare
Not too long ago, I wrote about a presentation that was delivered by GSK at IBM World of Watson 2016. While the pharmaceutical company’s use of Watson exhibits the advancement of artificial intelligence and machine learning, especially when it comes to advertising and marketing, there is another presentation from that event that is incredibly worthy […]
Some Rare Disease Stats That Make Them Seem Rather Common
We often hear the term “rare disease,” yet many of us still wonder exactly how “rare” is defined. In a recent blog post, Dr. Jonathan Goldsmith, the FDA’s Associate Director for Rare Diseases, shared some staggering statistics, as well as insights into how the FDA is making it easier to develop drugs for unusual […]
Don’t Be Left In The Dust By Digital Transformation
It seems like every other day we’re reading about pharmaceutical companies developing mobile apps, or at the very least, investing in companies that develop them. And that’s for good reason: They work. They help researchers learn about disorders. They help educate patients on their conditions and provide treatment recommendations. They help with patient adherence. […]